Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates

Minerva Neurosciences reported Q3 2026 financial results with R&D expenses of $5.2M (up from $0.9M YoY) driven by the ongoing Phase 3 C19 trial of roluperidone for schizophrenia negative symptoms. Topline efficacy data from Phase A is expected in 2H 2027. The company maintains $77M in cash and positions roluperidone as the only late-stage candidate targeting negative symptoms. A KOL event is scheduled for November 12, 2026.